GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

GSK plcNYSE: GSK

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin holds steady near 73.1%

Gross margin was 73.1% in Q2 FY2026, up 0.2 pp from a year earlier. On a trailing-twelve-month basis it was 72.7%, up 1.4 pp year over year. Over 3 fiscal years it widened by 5.0 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
73.1%-2.4 pp QoQ
Last fiscal yearDec 2025
72.4%+1.2 pp YoY
LTMJun 2026
72.7%+1.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.2 pp——
1 year+1.2 pp——
3 years+5.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
72.4%
Year-over-year change
+1.2pp

Gross Margin vs competitors

How GSK compares with its peers on the latest reported figures

  • GSK's LTM Jun 2026 gross margin of 72.7% is the 8th highest of the 10 companies compared; the peer median is 74.4%.
  • Its year-over-year change of +1.4 pp is the 3rd highest of 10, against a peer median of +0.7 pp.
  • Over three fiscal years its change of +5.0 pp compares with a peer median of +1.4 pp.
GSK Competitors Peer median
Gross Margin for GSK and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202683.4% +0.8 pp+6.3 pp
NVONovo Nordisk A/SLTM Jun 202680.6% -3.3 pp-2.9 pp
AZNAstraZeneca PLCLTM Sep 202680.1% -2.3 pp+9.8 pp
MRKMerck & Co., Inc.LTM Jun 202675.4% -0.1 pp+1.3 pp
NVSNovartis AGLTM Jun 202674.4% -1.8 pp+1.7 pp
PFEPfizer Inc.LTM Jun 202673.2% +1.1 pp+8.3 pp
SNYSanofiLTM Jun 202673.0% +1.4 pp+1.4 pp
GSKGSK plcLTM Jun 202672.7% +1.4 pp+5.0 pp
AMGNAmgen Inc.LTM Jun 202672.7% +8.2 pp-4.9 pp
JNJJohnson & JohnsonLTM Sep 202668.8% +0.7 pp-1.4 pp
Peer median (excluding GSK) 74.4%+0.7 pp+1.4 pp

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue24.7B29.32B30.33B31.38B32.67B
Cost of Revenue8.16B9.55B8.57B9.05B9.02B
Gross Profit16.53B19.77B21.76B22.33B23.65B
Gross Margin66.9%67.4%71.8%71.2%72.4%
Research & Development5.02B5.49B6.22B6.4B7.53B
Selling, General & Admin7.07B8.37B9.39B11.02B9.09B
Operating Expenses12.18B13.34B15.02B18.31B15.31B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
EBITDA6.49B8.6B9.08B6.67B10.4B
EBITDA Margin26.3%29.3%29.9%21.3%31.8%
Operating Income4.36B6.43B6.75B4.02B8.34B
Operating Margin17.6%21.9%22.2%12.8%25.5%
Interest Income28M64.27M40M67.39M56M
Interest Expense784M855.53M775M657.58M687M
Other Income / Expenses(758M)(805M)(681M)(544M)(937M)
Income Before Tax3.6B5.63B6.06B3.48B7.4B
Pre-Tax Margin14.6%19.2%20.0%11.1%22.7%
Income Tax Expense83M707M756M526M1.11B
Net Income4.39B14.96B4.93B2.58B5.72B
Net Margin17.8%51.0%16.2%8.2%17.5%
EPS (Basic)2.747.442.441.262.82
EPS (Diluted)2.707.322.401.242.78
Weighted Avg Shares1.6B2.01B2.03B2.04B2.03B
Weighted Avg Shares (Diluted)1.62B2.04B2.06B2.07B2.06B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.